Boston Scientific Financial Statements (BSX)
|
|
|
|
Report date
|
|
|
23.02.2021 |
23.02.2022 |
23.02.2023 |
20.02.2024 |
21.02.2024 |
|
01.11.2024 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
9 913 |
11 888 |
12 682 |
14 240 |
14 240 |
|
15 910 |
|
Operating Income, bln rub |
|
|
1 044 |
2 043 |
1 649 |
2 343 |
2 343 |
|
2 757 |
|
EBITDA, bln rub |
? |
|
1 511 |
2 518 |
2 741 |
3 620 |
3 453 |
|
3 737 |
|
Net profit, bln rub |
? |
|
-140.0 |
1 041 |
698.0 |
1 593 |
1 593 |
|
1 789 |
|
|
OCF, bln rub |
? |
|
1 508 |
1 870 |
1 526 |
2 503 |
2 503 |
|
-1 140 913 |
|
CAPEX, bln rub |
? |
|
376.0 |
554.0 |
612.0 |
800.0 |
800.0 |
|
1 059 |
|
FCF, bln rub |
? |
|
1 132 |
1 316 |
914.0 |
1 703 |
1 703 |
|
-1 141 972 |
|
Dividend payout, bln rub
|
|
|
28.0 |
55.0 |
55.0 |
28.0 |
28.0 |
|
23.0 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
5.28% |
7.88% |
1.76% |
1.76% |
|
1.29% |
|
|
OPEX, bln rub |
|
|
5 719 |
6 304 |
6 646 |
7 478 |
7 478 |
|
7 722 |
|
Cost of production, bln rub |
|
|
3 510 |
3 760 |
4 003 |
4 345 |
4 345 |
|
5 452 |
|
R&D, bln rub |
|
|
1 143 |
1 204 |
1 323 |
1 414 |
1 414 |
|
1 519 |
|
Interest expenses, bln rub |
|
|
361.0 |
341.0 |
470.0 |
265.0 |
265.0 |
|
290.0 |
|
|
Assets, bln rub |
|
|
30 778 |
32 230 |
32 470 |
35 136 |
35 136 |
|
38 078 |
|
Net Assets, bln rub |
? |
|
15 327 |
16 623 |
17 574 |
19 281 |
19 282 |
|
20 708 |
|
Debt, bln rub |
|
|
9 539 |
9 451 |
9 282 |
9 492 |
9 492 |
|
11 258 |
|
Cash, bln rub |
|
|
1 734 |
1 925 |
928.0 |
865.0 |
865.0 |
|
2 502 |
|
Net debt, bln rub |
|
|
7 805 |
7 526 |
8 354 |
8 627 |
8 627 |
|
8 756 |
|
|
Ordinary share price, rub |
|
|
36.0 |
42.5 |
46.3 |
57.8 |
57.8 |
|
52.5 |
|
Number of ordinary shares, mln |
|
|
1 417 |
1 422 |
1 431 |
1 453 |
1 453 |
|
1 473 |
|
|
Market cap, bln rub |
|
|
50 930 |
60 419 |
66 189 |
83 998 |
83 998 |
|
77 346 |
|
EV, bln rub |
? |
|
58 735 |
67 945 |
74 543 |
92 625 |
92 625 |
|
86 102 |
|
Book value, bln rub |
|
|
-540 |
-1 485 |
-1 249 |
-1 109 |
-1 108 |
|
-79 |
|
|
EPS, rub |
? |
|
-0.10 |
0.73 |
0.49 |
1.10 |
1.10 |
|
1.21 |
|
FCF/share, rub |
|
|
0.80 |
0.93 |
0.64 |
1.17 |
1.17 |
|
-775.4 |
|
BV/share, rub |
|
|
-0.38 |
-1.04 |
-0.87 |
-0.76 |
-0.76 |
|
-0.05 |
|
|
EBITDA margin, % |
? |
|
15.2% |
21.2% |
21.6% |
25.4% |
24.2% |
|
23.5% |
|
Net margin, % |
? |
|
-1.41% |
8.76% |
5.50% |
11.2% |
11.2% |
|
11.2% |
|
FCF yield, % |
? |
|
2.22% |
2.18% |
1.38% |
2.03% |
2.03% |
|
-1 476% |
|
ROE, % |
? |
|
-0.91% |
6.26% |
3.97% |
8.26% |
8.26% |
|
8.64% |
|
ROA, % |
? |
|
-0.45% |
3.23% |
2.15% |
4.53% |
4.53% |
|
4.70% |
|
|
P/E |
? |
|
-363.8 |
58.0 |
94.8 |
52.7 |
52.7 |
|
43.2 |
|
P/FCF |
|
|
45.0 |
45.9 |
72.4 |
49.3 |
49.3 |
|
-0.07 |
|
P/S |
? |
|
5.14 |
5.08 |
5.22 |
5.90 |
5.90 |
|
4.86 |
|
P/BV |
? |
|
-94.3 |
-40.7 |
-53.0 |
-75.7 |
-75.8 |
|
-979.1 |
|
EV/EBITDA |
? |
|
38.9 |
27.0 |
27.2 |
25.6 |
26.8 |
|
23.0 |
|
Debt/EBITDA |
|
|
5.17 |
2.99 |
3.05 |
2.38 |
2.50 |
|
2.34 |
|
|
R&D/CAPEX, % |
|
|
304.0% |
217.3% |
216.2% |
176.8% |
176.8% |
|
143.4% |
|
|
CAPEX/Revenue, % |
|
|
3.79% |
4.66% |
4.83% |
5.62% |
5.62% |
|
6.66% |
|
| Boston Scientific shareholders |
